RT Generic
T1 Efficacy and safety of endoscopic balloon dilation in inflammatory bowel disease: results of the large multicenter study of the ENEIDA registry (vol 34, pg 1112, 2020)
A1 Andujar, Xavier
A1 Loras, Carme
A1 Gonzalez, Begona
A1 Socarras, Milena
A1 Sanchiz, Vicente
A1 Bosca, Maia
A1 Domenech, Eugeni
A1 Calafat, Margalida
A1 Rodriguez, Esther
A1 Sicilia, Beatriz
A1 Calvet, Xavier
A1 Barrio, Jesus
A1 Guardiola, Jordi
A1 Iglesias, Eva
A1 Casanova, Maria Jose
A1 Ber, Yolanda
A1 Monfort, David
A1 Lopez-Sanroman, Antonio
A1 Rodriguez-Lago, Iago
A1 Bujanda, Luis
A1 Marquez, Lucia
A1 Martin-Arranz, Maria Dolores
A1 Zabana, Yamile
A1 Fernandez-Banares, Fernando
A1 Esteve, Maria
K1 Endoscopic balloon dilation
K1 Infammatory bowel disease
K1 Crohn’s disease
AB Javier P. Gisbert was listed incorrectly as Javier Perez-Gisbert.
AB There is no information regarding the outcome of Crohn’s disease (CD) patients treated with endoscopic balloon dilation (EBD) in non-referral hospitals, nor on the efficacy of EBD in ulcerative colitis (UC). We report herein the results of the largest series published to date. Aim: To assess the efficacy and safety of EBD for inflammatory bowel disease (IBD) stenosis performed in 19 hospitals with different levels of complexity and to determine factors related to therapeutic success. Methods: We identified IBD patients undergoing EBD in the ENEIDA database. Efficacy of EBD was compared between CD and UC and between secondary and tertiary hospitals. Predictive factors of therapeutic success were assessed with multivariate analysis. Results: Four-hundred dilations (41.2% anastomotic) were performed in 187 IBD patients (13 UC/Indeterminate colitis). Technical and therapeutic success per dilation was achieved in 79.5% and 55.3%, respectively. Therapeutic success per patient was achieved in 78.1% of cases (median follow-up: 40 months) with 49.7% requiring more than one dilation. No differences related to either diagnosis or hospital complexity was found. Technical success [OR 4.12 (95%CI 2.4–7.1)] and not receiving anti-TNF at the time of dilation [OR 1.7 (95% CI 1.1–2.6)] were independently related to therapeutic success per dilation. A stricture length ≤ 2 cm [HR 2.43 (95% CI 1.11–5.31)] was a predictive factor of long-term success per patient. The rate of major complications was 1.3%.
PB Springer
SN 0930-2794
YR 2019
FD 2019-05-29
LK http://hdl.handle.net/10668/18634
UL http://hdl.handle.net/10668/18634
LA en
NO Andújar X, Loras C, González B, Socarras M, Sanchiz V, Boscà M, et al. Efficacy and safety of endoscopic balloon dilation in inflammatory bowel disease: results of the large multicenter study of the ENEIDA registry. Surg Endosc. 2020 Mar;34(3):1112-1122
DS RISalud
RD Aug 1, 2025